Migraine is a highly prevalent and disabling neurovascular disorder, that predominantly affects women, thought to be associated with a dysfunctional activation of the trigeminovascular system. Despite the high prevalence of migraine, not all patients respond to current treatment. Moreover, the gold standard for acute treatment (“triptans”), are contraindicated in patients with cardiovascular disease due to their action in coronary blood vessels and migraine patients have higher risk of cardiovascular events. Additionally, the drugs available for the preventative treatment were not originally developed for migraine.
Thus, novel treatments that do not act on the coronary blood vessels and are developed based on the pathophysiology of migraine are needed. In this thesis, we set out to investigate whether the novel antimigraine drugs atogepant, erenumab, lasmiditan and ubrogepant act on the blood vessels. We also studied whether the antihypertensive propranolol, currently given as migraine preventative acts on the trigeminovascular system. Our results show that atogepant, erenumab, lasmiditan and ubrogepant are all devoid of vascular effects and that propranolol modulates the trigeminovascular system in a sex dependent manner.

, , , , , , , ,
A.H.J. Danser (Jan) , A. Maassen van den Brink (Antoinette)
Erasmus University Rotterdam
The author received a grant to pursue her doctoral studies at the Erasmus MC from the National Council of Science and Technology of Mexico (CONACyT), fellowship No. 409865.
Department of Pharmacology

Rubio-Beltrán, E. (2019, September 26). Vascular Effects of Current and Novel Antimigraine Drugs. Retrieved from http://hdl.handle.net/1765/119145